News

Immuno-oncology Firm Advances Lead Asset in Mesothelioma

June 17, 2021 (Investorideas.com Newswire) The status of ONCOS-102 in several of Targovax’s development programs is discussed in an H.C. Wainwright & Co. report.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

Next Article:

0 %